US 12,403,113 B2
Composition containing creatine fatty ester for use in medicine
Aloïse Mabondzo, Paris (FR); Gabriela Ullio-Gamboa, GIF s/ Yvette (FR); Anne-Cécile Guyot, Rueilmalmaison (FR); Sophie Dezard, Forges les Bains (FR); Frédéric Taran, GIF s/ Yvette (FR); Henri Benech, Paris (FR); and Olivier Loreau, St Michel s/ Orge (FR)
Assigned to COMMISSARIAT À L'ÉNERGIE ATOMIQUE ET AUX ÉNERGIES ALTERNATIVES, Paris (FR)
Appl. No. 17/594,629
Filed by COMMISSARIAT À L'ÉNERGIE ATOMIQUE ET AUX ÉNERGIES ALTERNATIVES, Paris (FR)
PCT Filed Apr. 29, 2020, PCT No. PCT/EP2020/061824
§ 371(c)(1), (2) Date Oct. 25, 2021,
PCT Pub. No. WO2020/221780, PCT Pub. Date Nov. 5, 2020.
Claims priority of application No. 19305548 (EP), filed on Apr. 30, 2019.
Prior Publication US 2022/0211651 A1, Jul. 7, 2022
Int. Cl. A61K 31/201 (2006.01); A61K 31/202 (2006.01); A61K 45/06 (2006.01); A61P 25/00 (2006.01)
CPC A61K 31/201 (2013.01) [A61K 31/202 (2013.01); A61K 45/06 (2013.01); A61P 25/00 (2018.01)] 13 Claims
OG exemplary drawing
 
1. A composition for use in medicine, said composition comprising at least one creatine fatty ester or salt thereof in an amount of 0.01% to 6% by weight based on the total weight of the composition, at least one omega 3 fatty acid or salt thereof in an amount of 15% to 35% by weight based on the total weight of the composition and at least one glyceride in an amount of 60% to 85% by weight based on the total weight of the composition, said composition being free of non ionic surfactants.